TNF and rheumatoid arthritis: Discordantly, an on-going, open-label, postmarketing clinical study evaluating the safety of tofacitinib compared with TNF inhibitors (etanercept or adalimumab) in patients with RA demonstrated that tofacitinib was associated with increased mortality, which was partially attributable to the increased SI risk, vs. TNF inhibitors [81].